ELDN Company Profile and Key Details

ELDN has shown mixed momentum, gaining 15.71% over the past week and -35.76% over the past quarter, though year-to-date performance is up 46.36%. Short-term trend indicators are mixed aligned (SMA20 10.88%, SMA50 23.32%, SMA200 -6.56%). The stock’s 14-day RSI is 64.83 (firm momentum), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.39% below its high and over 79.26% above its low. Average 10-day trading volume of 1.20 million shares is below the 3-month average of 1.48 million, indicating normal recent market interest.

Eledon Pharmaceuticals, Inc. has 59.88 million shares outstanding. The public float is 39.76 million shares, elevated short interest at 10.20% of float. This equals 5.46 million shares. The short ratio is 5.83 days. Institutional investors hold 73.28% of the float. Insiders own 1.4%. Harrison Seth Loring holds 7.91 million shares, Novartis Bioventures Ltd has 4.49 million shares and Apple Tree Partners II - Annex, L.P. has 3.57 million shares.

Eledon Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

Eledon Pharmaceuticals, Inc. generated EPS of -$1.20 over the past year. Five-year average earnings growth is 50.24%. Wall Street analysts project EPS growth of -3.99% annually over the next five years. The latest quarter delivered EPS of -$18.25. The next quarter is forecast at -$0.20. Next year's EPS is expected at $26.04. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $8.00. The high target offers 208.48% upside. The low target suggests 105.66% downside. The mean target is $10.57. This offers 171.72% upside. Eledon Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by 8195.45%. The prior quarter beat by -50.0%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in March 20, 2025.

The stock is currently mid-range between its 52-week high and low $1.35 and $4.60. With a market capitalization of about $233.06 million, Eledon Pharmaceuticals, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 1.47 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Eledon Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David-Alexandre C. Gros, the company employs approximately 31 people and listed since September 17, 2014. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

Eledon Pharmaceuticals, Inc. trades at a P/E ratio of -5.58, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.34 trading at moderately above to book value. The P/FCF stands at -3.38, also above market averages.

Our AI price prediction model suggests that Eledon Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.26%, with price expected at $3.90 by June 03, 2026, within a range of $3.63 to $4.16 3-Month Outlook: Projected fall of -63.24%, reaching $1.43 by August 19, 2026, with a range of $1.05 to $1.58. 1-Year Outlook: Projected gain of 397.94%, with price at $19.37 by May 21, 2027, within a range of $2.72 to $31.30.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) shares are up 46.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eledon Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.73, suggesting 252.96% upside. Our AI forecast model points to short-term strength (0.26% over two weeks), a medium-term fall (-63.24% over three months), and a longer-term gain (397.94% over one year), with expected trading ranges indicating moderate volatility.